Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, bosentan (Tracleer®) cannot be endorsed for use within NHS Wales for the treatment of class II pulmonary arterial hypertension (license extension). |
||
|
||
Medicine details |
||
| Medicine name | bosentan (Tracleer®) | |
| Formulation | 62.5 mg and 125 mg film-coated tablet | |
| Reference number | 68 | |
| Indication | Treatment of class II pulmonary arterial hypertension |
|
| Company | Actelion Pharmaceuticals UK Ltd | |
| BNF chapter | Cardiovascular system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 01/09/2011 | |